TSE:BHC Stock Earnings Estimates Boosted by Zacks Research

Bausch Health Companies Inc. (TSE:BHC – Free Report) – Analysts at Zacks Research raised their FY2026 earnings per share (EPS) estimates for shares of Bausch Health Companies in a research note issued on Wednesday, November 18th. Zacks Research analyst Team now expects that the company will post earnings per share of $7.11 for the year, up from their previous forecast of $5.95. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2028 earnings at $1.02 EPS.

Bausch Health Companies Trading Down 1.8%

BHC opened at C$12.30 on Friday. The company has a debt-to-equity ratio of -1,559.86, a quick ratio of 0.58 and a current ratio of 1.56. The stock’s 50 day moving average price is C$9.55 and its 200-day moving average price is C$8.16. Bausch Health Companies has a one year low of C$6.10 and a one year high of C$12.66. The stock has a market cap of C$4.60 billion, a price-to-earnings ratio of -5.44, a P/E/G ratio of 0.21 and a beta of 0.73.

Bausch Health Companies (TSE:BHC – Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported C$2.52 EPS for the quarter. Bausch Health Companies had a positive return on equity of 57.67% and a negative net margin of 7.43%. The firm had revenue of C$4.19 billion during the quarter.

Bausch Health Companies declared that its Board of Directors has approved a stock repurchase plan on Wednesday, October 28th that permits the company to buy back C$70 million in outstanding shares. This buyback authorization permits the company to reacquire up to 1.9% of its shares through open market purchases. Stock buyback plans are often an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Bausch Health Companies

In related news, insider Mirza Dautbegovic sold 20,000 shares of the firm’s stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of C$11.18, for a total value of C$223,600.00. Following the transaction, the insider owned 224,745 shares of the company’s stock, valued at C$2,512,649.10. This trade represents a 8.17% decrease in their position. Company insiders own 11.28% of the company’s stock.

Key Stories Impacting Bausch Health Companies

Here are a few of the latest stories about BHC:

  • Positive Sentiment: Zacks raised its FY2026 EPS estimate to $7.11 from $5.95 and its FY2027 estimate to $5.56 from $5.40. It also lifted several quarterly estimates, including Q4 2026 to $1.67 and Q1 and Q2 2027 to $1.21 and $1.36, respectively. These revisions suggest a more optimistic earnings view for those periods. MarketBeat report
  • Positive Sentiment: Zacks modestly increased its FY2028 EPS estimate to $4.32 from $4.28, and raised estimates for Q1, Q2 and Q4 2027 and Q1 and Q2 2028. MarketBeat report
  • Negative Sentiment: Zacks cut its Q3 2028 EPS estimate to $1.02 from $1.14, a downgrade that partially offsets the positive revisions. MarketBeat report

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

Featured Articles

Earnings History and Estimates for Bausch Health Companies (TSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.